Autolus Therapeutics plc (AUTL) Stock Analysis
A live, multi-source view of Autolus Therapeutics plc (AUTL): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Sector: Healthcare · Industry: Biotechnology · United Kingdom · 752 employees · autolus.com
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Autolus Therapeutics plc (AUTL) last closed at $2.03 (the last completed close before that scan).
Technicals at the scan: RSI 44 (neutral territory), price -11.4% versus its 20-day average, 20-day versus 50-day average spread +20.5%, MACD histogram -0.06.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 78/100.
Next scheduled company event: in 67 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of AUTL; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-09-03). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Cintia Piccina (0B/1S). Who is trading what
RapidTradeView pick record
AUTL has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Autolus Therapeutics plc (AUTL) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell AUTL.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.